Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Monday, July 27, 2020 8:09:17 AM
July 27 2020 - 07:58AM
PR Newswire (US) Print
NEW YORK, July 27, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.
On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn® (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.
Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Monday, August 3, 2020.
Teleconference Details – BRAINSTORM CELL THERAPEUTICS 2Q 2020
The investment community may participate in the conference call by dialing the following numbers:
Participant Numbers:
Toll Free: 877-407-9205
International: 201-689-8054
Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at www.ir.brainstorm-cell.com and clicking on the conference call link.
Event Link:
Webcast URL:
https://bit.ly/2DciAC9
Webcast Replay Expiration:
Thursday, August 05, 2021
Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.
Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 36017
Teleconference Replay Expiration:
Wednesday, August 19, 2020
Recent BCLI News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/17/2024 07:32:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:36:41 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:04 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/28/2024 09:01:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/16/2024 11:00:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:21 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 08/06/2024 08:59:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/05/2024 09:11:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:18 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (Canada) • 07/24/2024 12:30:00 PM
- BCLI Update - Progress Supports Our 10x Plus Value Range Potential • PR Newswire (US) • 07/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:57 PM
- Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (US) • 06/14/2024 04:01:00 PM
- Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation • PR Newswire (Canada) • 06/14/2024 04:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 10:05:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM